Hyperliquid Strategies (PURR) selling stockholder offers 35.2M shares at $1.00/share; company receives no proceeds from secondary sale

Rorschach Advisors LLC is offering 35,156,660 shares for sale. This is a secondary offering by a selling stockholder; proceeds go to Rorschach Advisors LLC, not to the company.

The 35,156,660 shares held by Rorschach Advisors LLC consist of 7,761,860 directly issued shares and 27,394,800 shares issuable upon warrant exercise. The warrants are subject to adjustment provisions.

After this offering, Rorschach Advisors LLC will beneficially own zero shares of Common Stock, having sold its entire position.

At the December 2, 2025 closing of the merger transactions, the company held approximately $580 million in HYPE tokens (valued at an agreed spot price of $46.372 per token) and approximately $310 million in cash, before transaction expenses. These holdings represent the company's primary assets as a treasury-focused entity.

The company issued 7,761,860 shares (5% of fully-diluted shares at closing) and warrants to purchase 27,394,800 shares (15% of fully-diluted shares) to its advisor at closing. The warrants have five-year terms with exercise prices of $9.375, $12.50, and $18.75 (one-third at each price). This represents substantial dilution and ongoing advisory fees tied to future equity raises.

The company has a committed equity facility with Chardan allowing it to sell up to $1.0 billion of common stock at its discretion after this registration statement becomes effective. The company states it plans to use proceeds primarily for additional HYPE token purchases and general corporate purposes. This facility represents potential substantial dilution to existing shareholders.

On March 31, 2026, the company disposed of Sonnet's biotechnology assets to a newly-formed entity, Guidant, transferring $1.325 million in cash, developmental assets, patents, employees, and Sonnet's Australian subsidiary, plus a $1.0 million deferred payment. In exchange, the company received a 40% equity stake in Guidant. This transaction effectively exits the company from the biotechnology business acquired in the December 2025 merger.

The company identifies HYPE as a highly volatile asset subject to significant legal and regulatory uncertainty. Because the company's treasury strategy centers on holding HYPE tokens, price fluctuations in HYPE will directly affect financial results and the stock price, and the strategy subjects the company to enhanced regulatory oversight.

The company will receive zero proceeds from the shares being sold by the selling stockholder. This is a secondary offering component where proceeds go to the selling stockholder, not to the company.

The company could receive up to approximately $371.0 million in gross proceeds if all Advisor Warrants are exercised for cash. However, the filing notes the warrants may expire unexercised or be exercised on a cashless basis (yielding no cash), making actual proceeds uncertain.

Any cash proceeds from warrant exercises will be used primarily to purchase HYPE Tokens and for general corporate purposes. The company retains broad discretion over the use of these proceeds.

Neither predecessor entity has ever paid dividends, and the company does not anticipate paying cash dividends in the foreseeable future, instead retaining earnings for business development and operations.

As of May 19, 2026, the common stock traded at $7.79 per share on Nasdaq with 144,447,571 shares outstanding held by 63 record holders (actual beneficial ownership is higher as many shares are held through brokers).

The company discloses that HYPE token price has ranged from $10.26 to $58.96 over approximately 18 months, a 5.7x range. The company's treasury strategy centers on holding HYPE, so this volatility directly affects the company's asset value and stock price. The filing states the company expects to see volatility in its stock price due to its cryptocurrency treasury strategy and investor perception that the stock value is linked to HYPE holdings.

The company states it does not believe it is an investment company because HYPE is not a security, but acknowledges a regulator or court may determine otherwise. If deemed an investment company, restrictions under the Investment Company Act would make it impractical to continue the business as contemplated, including limitations on issuing different classes of stock and equity compensation. The filing notes this would have a material adverse effect on the business.

The company discloses two major DeFi exploits in April 2026 totaling approximately $577 million, demonstrating that even established protocols remain susceptible to sophisticated attacks. The company holds a material portion of its assets in HYPE tokens on the Hyperliquid blockchain, and states that any security breach or exploit could result in partial or total loss of $ 152,510 HYPE holdings, materially adversely affecting financial condition and causing a significant decline in stock price.

The company discloses that all its HYPE holdings are currently held with a single custodian, Anchorage Digital Bank. The filing states that any insurance covering HYPE losses may cover only a small fraction of total holdings, may be subject to aggregate limits shared among all customers, and may exclude certain risks like smart contract failures. In a large-scale incident, total claims could exceed policy limits, leading to insufficient payouts that may not fully compensate the company for losses.

The company's treasury strategy concentrates assets in HYPE tokens rather than a diversified portfolio. This means any decline in HYPE's price will have a magnified impact on the company's financial condition compared to holding a mix of assets. The company acknowledges it is forgoing the risk mitigation that diversification would provide.

Starting November 2025, 238 million HYPE tokens (23.8% of total supply) allocated to core contributors began monthly vesting after a one-year lockup. The filing warns this substantial token unlock may introduce significant selling pressure, heightened price volatility, downward pressure on HYPE's market value, and dilution of the company's proportional ownership. The specific vesting schedule and unlock amounts are not publicly known.

The Hyperliquid protocol is governed by validator votes weighted by staked HYPE, requiring two-thirds support to pass changes. As 238 million tokens vest to the Foundation and core contributors starting November 2025, these insiders may control or significantly influence a majority of voting weight. This concentration means insiders could determine protocol changes (tokenomics, fee structures, staking economics) that benefit them at the expense of other HYPE holders, with no fiduciary duty or formal governance protections for minority holders.

The Hyperliquid Network's HyperBFT consensus has specific attack thresholds: validators controlling over one-third of staked HYPE could halt transaction processing (liveness attack), preventing the company from accessing its HYPE holdings; validators controlling over two-thirds could reverse confirmed transactions or manipulate ledger state (safety attack). The filing warns that as core contributor tokens vest and are staked, concentration of stake with a small number of validators may make these attack thresholds more achievable.

The company reported a net loss of $165.4 million for the nine months ended March 31, 2026, and an accumulated deficit of $165.9 million as of that date. The quarterly net income of $2.6 million for the three months ended March 31, 2026 was driven by a $198.4 million unrealized gain on HYPE tokens, offset by $42.7 million in income tax expense. The nine-month loss includes a $169.2 million loss on the HYPE contribution commitment (the 12.5 million HYPE tokens declined in value from the original commitment amount) and a $35.6 million IPR&D write-off from the Sonnet acquisition.

The company held HYPE digital assets with a fair value of $689.0 million as of March 31, 2026, alongside $113.1 million in cash and cash equivalents. The HYPE holdings consist of approximately 12.5 million tokens received via the HYPE Contributions at closing (valued at $411.3 million on the Closing Date) plus an additional 321,224 HYPE tokens purchased in December 2025 for approximately $9.0 million. The fair value increased by $105.2 million (unrealized gain) during the nine months ended March 31, 2026.

At the December 2, 2025 closing of the reverse recapitalization, the company raised gross proceeds of $880.4 million, consisting of $299.9 million in cash and 12,517,592 HYPE tokens valued at $580.5 million (based on the fair value of shares issued for the tokens). The PIPE and Contributions were converted into 123,354,259 shares of Common Stock and 166,173 shares of Series A Preferred Stock. Transaction costs of $2.3 million related to the PIPE financing were deducted from additional paid-in capital. The company recognized a $169.2 million loss on the HYPE contribution commitment because the approximately 12.5 million HYPE tokens were valued at $411.3 million on the Closing Date, down from the original commitment amount of $580.5 million.

Prior to the December 2, 2025 closing, both Rorschach (no cash, member's deficit of $596,667 at June 30, 2025) and the Company (no cash, stockholder's deficit of $2,425 at July 2, 2025) had substantial doubt about their ability to continue as a going concern. The capital raised through the Closing PIPE and the entry into the $1.0 billion committed equity facility with Chardan alleviated this substantial doubt. The company now expects its existing resources will be sufficient to fund operations for at least one year from the date the March 31, 2026 financial statements were issued.

The company generated $3.1 million in net staking revenue for the nine months ended March 31, 2026 (of which $2.6 million was earned in the three months ended March 31, 2026). Staking rewards are recognized as revenue when the company satisfies its performance obligations by providing tokens to the validator, measured at fair value at contract inception. Because the company does not control the validator, it presents staking rewards on a net basis with no cost of revenue.

The company's entire business model is managing a treasury of HYPE tokens, the native cryptocurrency of the Hyperliquid blockchain. This is an unusual business model for a public company — the company does not operate the blockchain itself, it simply holds and stakes the blockchain's native token. The company's financial condition is therefore entirely dependent on the market price and adoption of HYPE.

All of the company's HYPE token holdings — its primary treasury asset — are held with a single custodian. If that custodian fails to comply with contractual requirements or becomes insolvent, the company may lose access to its entire treasury. This is a significant operational and counterparty risk.

For the nine months ended March 31, 2026, the company reported a GAAP net loss of $165.4 million attributable to common stockholders. The three-month period ended March 31, 2026 showed net income of $125.6 million, but the nine-month cumulative result is a substantial loss. This loss reflects the company's early-stage operations and the volatility of its HYPE token holdings.

The Advisor received $183.6 million in equity at closing and holds proportional board nomination rights (including the Chairman seat) as long as it maintains at least 10% ownership. Additionally, the Advisor is entitled to receive 5% of shares and 15% of warrants in any future equity financing during a five-year advisory term, creating ongoing dilution tied to future capital raises.

The company received 12.5 million HYPE tokens from investors as part of $880.4 million in gross proceeds at closing. However, the filing also states "at Closing, such 12.5 million HYPE tokens were valued at $411.3 million, resulting in a loss on commitment of $169.2 million recognized by the Company on the HYPE tokens," indicating the tokens were marked down immediately by $169.2 million from the $580.5 million fair value of shares issued.

The company issued three tranches of warrants to the Advisor (exercisable at $9.375, $12.50, and $18.75 per share) with a combined fair value of $134.7 million, using HYPE token volatility of 123% as a key input. Each warrant tranche covers 9,131,600 shares (27.4 million shares total) and expires five years from closing.

The company disposed of Sonnet's tumor-delivery platform assets (acquired in the December 2025 reverse merger) to Guidant for $1.325 million in cash plus a $1.0 million deferred payment, receiving a 40% equity stake in Guidant in return. This suggests the company is exiting the biotech business it acquired through Sonnet and focusing solely on its HYPE token treasury strategy.

The company wrote off $35.6 million of in-process R&D acquired from Sonnet, recognizing it had no alternative future use. This write-off, combined with the subsequent sale of Sonnet's assets to Guidant, indicates the company acquired Sonnet primarily for its cash/public listing rather than its biotech pipeline.